Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusion Antibodies Plc ( (GB:FAB) ) has shared an update.
Fusion Antibodies plc announced the successful validation of its OptiMAL® platform for isolating specific antibodies against both protein and peptide targets, marking a significant milestone in its collaboration with the National Cancer Institute. This development positions the company for the commercial launch of OptiMAL® in December 2025 and expands its market potential by enabling the use of the platform for a wider range of targets. The NCI has expressed interest in extending its agreement with Fusion, highlighting the platform’s potential as a leading tool in therapeutic antibody discovery.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £14.00 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics highlight the company’s unprofitability. The absence of earnings call data and corporate events leaves these areas unaddressed.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a broad range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top 10 global pharmaceutical companies by revenue, and aims to accelerate drug development through innovative platforms.
Average Trading Volume: 1,482,012
Technical Sentiment Signal: Buy
Current Market Cap: £15.34M
See more data about FAB stock on TipRanks’ Stock Analysis page.